Your browser doesn't support javascript.
loading
Targeting PDE4B (Phosphodiesterase-4 Subtype B) for Cardioprotection in Acute Myocardial Infarction via Neutrophils and Microcirculation.
Wan, Qing; Xu, Chuansheng; Zhu, Liyuan; Zhang, Yuze; Peng, Zekun; Chen, Hong; Rao, Haojie; Zhang, Erli; Wang, Hongyue; Chu, Fei; Ning, Xuan; Yang, Xuejian; Yuan, Jinqing; Wu, Yongjian; Huang, Yu; Hu, Shengshou; Liu, De-Pei; Wang, Miao.
Afiliação
  • Wan Q; State Key Laboratory of Cardiovascular Disease (Q.W., C.X., L.Z., Y.Z., Z.P., H.C., H.R., F.C., X.N., X.Y., S.H., M.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Xu C; State Key Laboratory of Cardiovascular Disease (Q.W., C.X., L.Z., Y.Z., Z.P., H.C., H.R., F.C., X.N., X.Y., S.H., M.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhu L; State Key Laboratory of Cardiovascular Disease (Q.W., C.X., L.Z., Y.Z., Z.P., H.C., H.R., F.C., X.N., X.Y., S.H., M.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhang Y; State Key Laboratory of Cardiovascular Disease (Q.W., C.X., L.Z., Y.Z., Z.P., H.C., H.R., F.C., X.N., X.Y., S.H., M.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Peng Z; State Key Laboratory of Cardiovascular Disease (Q.W., C.X., L.Z., Y.Z., Z.P., H.C., H.R., F.C., X.N., X.Y., S.H., M.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Chen H; State Key Laboratory of Cardiovascular Disease (Q.W., C.X., L.Z., Y.Z., Z.P., H.C., H.R., F.C., X.N., X.Y., S.H., M.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Rao H; State Key Laboratory of Cardiovascular Disease (Q.W., C.X., L.Z., Y.Z., Z.P., H.C., H.R., F.C., X.N., X.Y., S.H., M.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhang E; Department of Cardiology (E.Z., J.Y., Y.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wang H; Department of Pathology (H.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Chu F; State Key Laboratory of Cardiovascular Disease (Q.W., C.X., L.Z., Y.Z., Z.P., H.C., H.R., F.C., X.N., X.Y., S.H., M.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Ning X; Department of Pharmacy, First Affiliated Hospital, Bengbu Medical College, Anhui, China (F.C.).
  • Yang X; State Key Laboratory of Cardiovascular Disease (Q.W., C.X., L.Z., Y.Z., Z.P., H.C., H.R., F.C., X.N., X.Y., S.H., M.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Yuan J; State Key Laboratory of Cardiovascular Disease (Q.W., C.X., L.Z., Y.Z., Z.P., H.C., H.R., F.C., X.N., X.Y., S.H., M.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wu Y; Department of Cardiology (E.Z., J.Y., Y.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Huang Y; Department of Cardiology (E.Z., J.Y., Y.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Hu S; Department of Biomedical Sciences, The City University of Hong Kong, Hong Kong SAR, China (Y.H.).
  • Liu DP; State Key Laboratory of Cardiovascular Disease (Q.W., C.X., L.Z., Y.Z., Z.P., H.C., H.R., F.C., X.N., X.Y., S.H., M.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Wang M; Department of Cardiovascular Surgery (S.H.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Circ Res ; 131(5): 442-455, 2022 08 19.
Article em En | MEDLINE | ID: mdl-35899614
ABSTRACT

BACKGROUND:

Timely and complete restoration of blood flow is the most effective intervention for patients with acute myocardial infarction. However, the efficacy is limited by myocardial ischemia-reperfusion (MI/R) injury. PDE4 (phosphodiesterase-4) hydrolyzes intracellular cyclic adenosine monophosphate and it has 4 subtypes A-D. This study aimed to delineate the role of PDE4B (phosphodiesterase-4 subtype B) in MI/R injury.

METHODS:

Mice were subjected to 30-minute coronary artery ligation, followed by 24-hour reperfusion. Cardiac perfusion was assessed by laser Doppler flow. Vasomotor reactivities were determined in mouse and human coronary (micro-)arteries.

RESULTS:

Cardiac expression of PDE4B, but not other PDE4 subtypes, was increased in mice following reperfusion. PDE4B was detected primarily in endothelial and myeloid cells of mouse and human hearts. PDE4B deletion strikingly reduced infarct size and improved cardiac function 24-hour or 28-day after MI/R. PDE4B in bone marrow-derived cells promoted MI/R injury and vascular PDE4B further exaggerated this injury. Mechanistically, PDE4B mediated neutrophil-endothelial cell interaction and PKA (protein kinase A)-dependent expression of cell adhesion molecules, neutrophil cardiac infiltration, and release of proinflammatory cytokines. Meanwhile, PDE4B promoted coronary microcirculatory obstruction and vascular permeability in MI/R, without affecting flow restriction-induced thrombosis. PDE4B blockade increased flow-mediated vasodilatation and promoted endothelium-dependent dilatation of coronary arteries in a PKA- and nitric oxide-dependent manner. Furthermore, postischemia administration with piclamilast, a PDE4 pan-inhibitor, improved cardiac microcirculation, suppressed inflammation, and attenuated MI/R injury in mice. Incubation with sera from patients with acute myocardial infarction impaired acetylcholine-induced relaxations in human coronary microarteries, which was abolished by PDE4 inhibition. Similar protection against MI/R-related coronary injury was recapitulated in mice with PDE4B deletion or inhibition, but not with the pure vasodilator, sodium nitroprusside.

CONCLUSIONS:

PDE4B is critically involved in neutrophil inflammation and microvascular obstruction, leading to MI/R injury. Selective inhibition of PDE4B might protect cardiac function in patients with acute myocardial infarction designated for reperfusion therapy.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Traumatismo por Reperfusão Miocárdica / Infarto do Miocárdio Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Traumatismo por Reperfusão Miocárdica / Infarto do Miocárdio Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article